Clinical Trials Browser

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05461794 2025-06-13

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Phase 2 Terminated

96 enrolled 17 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

423 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT04925986 2025-04-17

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Phase 2 Terminated

9 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT04123704 2024-08-26

Sitravatinib in Metastatic Breast Cancer

Phase 2 Terminated

3 enrolled 13 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02978859 2024-07-18

Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas

Phase 2 Completed

29 enrolled 11 charts

Sarcoma

Liposarcoma, Sarcoma

NCT02954991 2024-04-22

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Phase 2 Terminated

161 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04727996 2024-04-19

BTC-BGB

Phase 2 Active not recruiting

43 enrolled

Gastrointestinal

Advanced Biliary Tract Cancer

NCT05176925 2024-01-29

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

Phase 2 Terminated

5 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04734262 2023-11-18

SPARK

Phase 2 Unknown

98 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05228496 2023-09-26

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

Phase 2 Unknown

21 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03606174 2023-08-24

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Phase 2 Terminated

260 enrolled 28 charts

Genitourinary

Carcinoma, Transitional Cell

NCT05614453 2023-06-29

ITTACC

Phase 2 Withdrawn

Gynecologic

Uterine Cervical Neoplasms

NCT05407519 2023-03-22

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05419817 2023-02-27

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Phase 2 Withdrawn

Gynecologic

Endometrial Neoplasms

NCT05104801 2021-11-04

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Phase 2 Unknown

37 enrolled

Dermatologic

Melanoma

Clinical Trials

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Sitravatinib in Metastatic Breast Cancer

Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

BTC-BGB

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

SPARK

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

ITTACC

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma